A Phase 1, Open-Label Clinical Trial

Primary: • To evaluate the safety and tolerability of multiple ascending doses of intradermally (ID) administered LV305 in patients with locally advanced, relapsed, or metastatic cancer expressing NY-ESO-1 up through seven days after the second injection of LV305 (Study Day 28) • Part 2, Site-Specific Amendment: Assess the safety and tolerability of LV305 and pembrolizumab therapy used as treatment in eligible melanoma patients who have had an inadequate response to prior anti-PD-1 therapy

July 03, 2017